Signaturefd, LLC Pliant Therapeutics, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 124 shares of PLRX stock, worth $1,527. This represents 0.0% of its overall portfolio holdings.

Number of Shares

124

Holding current value

$1,527

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$10.52 - $14.35 $1,304 - $1,779	124 New	124 $1,000
Q1 2024 May 03, 2024	SELL	$14.14 - $19.59 $523 - $724	-37 Reduced 8.15%	417 $6,000
Q4 2023 Jan 31, 2024	SELL	$12.85 - $19.15 $1,837 - $2,738	-143 Reduced 23.95%	454 $8,000
Q3 2023 Nov 03, 2023	BUY	$14.58 - $20.15 $7,290 - $10,075	500 Added 515.46%	597 $10,000
Q2 2023 Aug 01, 2023	BUY	$18.12 - $30.56 $688 - $1,161	38 Added 64.41%	97 $1,000
Q1 2023 Apr 28, 2023	SELL	$18.73 - $36.26 $693 - $1,341	-37 Reduced 38.54%	59 $1,000
Q4 2022 Jan 27, 2023	SELL	$17.0 - $25.43 $1,411 - $2,110	-83 Reduced 46.37%	96 $1,000
Q3 2022 Nov 08, 2022	BUY	$7.67 - $24.23 $920 - $2,907	120 Added 203.39%	179 $4,000
Q2 2022 Aug 10, 2022	BUY	$4.11 - $8.75 $242 - $516	59 New	59 $0

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

Deep Track Capital, LP Greenwich, CT

5.97M
Shares

$73.6 Million
2.47% of portfolio
Black Rock Inc. New York, NY

4.97M
Shares

$61.3 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.83M
Shares

$59.6 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

3.53M
Shares

$43.4 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

3.2M
Shares

$39.4 Million
2.34% of portfolio

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account